These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9613341)

  • 21. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
    Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
    ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study.
    Luo G; Garner CE; Xiong H; Hu H; Richards LE; Brouwer KL; Duan J; Decicco CP; Maduskuie T; Shen H; Lee FW; Gan LS
    Drug Metab Dispos; 2007 Jun; 35(6):835-40. PubMed ID: 17332143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.
    Bressolle F; Bologna C; Edno L; Bernard JC; Gomeni R; Sany J; Combe B
    Eur J Clin Pharmacol; 1996; 49(4):285-92. PubMed ID: 8857074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate].
    Wiland P; Wiela-Hojeńska A; Swierkot J; Hurkacz M; Orzechowska-Juzwenko K; Szechiński J
    Pol Arch Med Wewn; 2003 Aug; 110(2):855-62. PubMed ID: 14682224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients.
    Combe B; Edno L; Lafforgue P; Bologna C; Bernard JC; Acquaviva P; Sany J; Bressolle F
    Br J Rheumatol; 1995 May; 34(5):421-8. PubMed ID: 7788170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis?
    Carpentier N; Bertin P; Marquet P; Sabot C; Bonnet C; Debord J; Lachâtre G; Trèves R
    J Rheumatol; 1998 Jul; 25(7):1270-5. PubMed ID: 9676755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
    Berenson JR; Rosen L; Vescio R; Lau HS; Woo M; Sioufi A; Kowalski MO; Knight RD; Seaman JJ
    J Clin Pharmacol; 1997 Apr; 37(4):285-90. PubMed ID: 9115053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication].
    Erdbrügger U; de Groot K
    Z Rheumatol; 2011 Sep; 70(7):549-52. PubMed ID: 21735288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis.
    Murosaki T; Nagatani K; Sato T; Akiyama Y; Ushijima K; Lefor AK; Fujimura A; Minota S
    Mod Rheumatol; 2017 May; 27(3):411-416. PubMed ID: 27435295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythrocyte methotrexate-polyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis.
    Inoue S; Hashiguchi M; Kawai S; Mochizuki M
    Yakugaku Zasshi; 2009 Aug; 129(8):1001-5. PubMed ID: 19652507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function.
    Konishi K; Suzuki H; Hayashi M; Saruta T
    J Antimicrob Chemother; 1993 Mar; 31(3):413-20. PubMed ID: 8486575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
    Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
    Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.
    Fathi NH; Mitros F; Hoffman J; Straniero N; Labreque D; Koehnke R; Furst DE
    J Rheumatol; 2002 Oct; 29(10):2092-8. PubMed ID: 12375317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.